In molecular biology, mir-145 microRNA is a short RNA molecule that in humans is encoded by the MIR145 gene. MicroRNAs function to regulate the expression levels of other genes by several mechanisms.[3]
Targets
MicroRNAs are involved in down-regulation of a variety of target genes. Götte et al. have shown that experimental over-expression of mir-145 down-regulates the junctional cell adhesion molecule JAM-A as well as the actin bundling protein fascin.[4] Larsson et al.[5] showed that miR-145 targets the 3' UTR of the FLI1 gene, a finding that was later supported by Zhang et al.[6]
^ abGötte M, Mohr C, Koo CY, Stock C, Vaske AK, Viola M, Ibrahim SA, Peddibhotla S, Teng YH, Low JY, Ebnet K, Kiesel L, Yip GW (Dec 2010). "miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness". Oncogene. 29 (50): 6569–80. doi:10.1038/onc.2010.386. PMID20818426.
^Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R (2007). "Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer". Oncology. 72 (5–6): 397–402. doi:10.1159/000113489. PMID18196926.
Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, Matsubara H (Dec 2010). "miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma". International Journal of Cancer. Journal International Du Cancer. 127 (12): 2804–14. doi:10.1002/ijc.25284. PMID21351259.
Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sørensen KD, Ulhøi B, Borre M, Kjems J, Dyrskjøt L, Orntoft TF (Feb 2010). "miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors". Oncogene. 29 (7): 1073–84. doi:10.1038/onc.2009.395. PMID19915607.
Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A (Jan 2010). "Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype". Nature Medicine. 16 (1): 49–58. doi:10.1038/nm.2054. PMID19898489.
Zhang C (Nov 2009). "MicroRNA-145 in vascular smooth muscle cell biology: a new therapeutic target for vascular disease". Cell Cycle. 8 (21): 3469–73. doi:10.4161/cc.8.21.9837. PMID19829088.
Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA (Feb 2010). "miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells". Cell Death and Differentiation. 17 (2): 246–54. doi:10.1038/cdd.2009.117. PMID19730444.
Cho WC, Chow AS, Au JS (Aug 2009). "Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation". European Journal of Cancer. 45 (12): 2197–206. doi:10.1016/j.ejca.2009.04.039. PMID19493678.
Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS (May 2009). "MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells". Cell. 137 (4): 647–58. doi:10.1016/j.cell.2009.02.038. PMID19409607.
La Rocca G, Badin M, Shi B, Xu SQ, Deangelis T, Sepp-Lorenzinoi L, Baserga R (Aug 2009). "Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway". Journal of Cellular Physiology. 220 (2): 485–91. doi:10.1002/jcp.21796. PMID19391107.
Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L, Zhou H, Zhao RC (May 2009). "miR-145 inhibits breast cancer cell growth through RTKN". International Journal of Oncology. 34 (5): 1461–6. PMID19360360.
Zheng L, Pu J, Qi T, Qi M, Li D, Xiang X, Huang K, Tong Q (Feb 2013). "miRNA-145 targets v-ets erythroblastosis virus E26 oncogene homolog 1 to suppress the invasion, metastasis, and angiogenesis of gastric cancer cells". Molecular Cancer Research. 11 (2): 182–93. doi:10.1158/1541-7786.MCR-12-0534. PMID23233482.